DOCSLIB.ORG

Download API Catalog

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download API Catalog Product Known Teva Tech US EU Japan Korea therapeutic api file*** DMF DMF DMF DMF area** IP A ABALOPARATIDE Osteoporosis ABEMACICLIB Oncology ABIRATERONE ACETATE Oncology ACALABRUTINIB Oncology ACYCLOVIR Dermatology CEP AFATINIB Oncology ALCLOMETASONE DIPROPIONATE Dermatology ALENDRONATE SODIUM* Osteoporosis ALLOPURINOL Rheumatology CEP AMCINONIDE Dermatology AMITRIPTYLINE HCl Neurology-Psychiatry CEP ANASTROZOLE Oncology CEP ANIDULAFUNGIN Infectious disease APALUTAMIDE* Oncology APIXABAN Coagulation Inhibitors APREMILAST* Psoriasis ARIPIPRAZOLE* Neurology-Psychiatry ATENOLOL Cardiovascular CEP ATOMOXETINE HCl Neurology-Psychiatry ATORVASTATIN CALCIUM Lipid lowering CEP ATOSIBAN ACETATE Preterm labor prevention ATRACURIUM BESYLATE Muscle relaxant CEP AZACITIDINE Oncology AZITHROMYCIN DIHYDRATE Infectious disease CEP AZTREONAM* Infectious disease B BARICITINIB Rheumatology BECLOMETHASONE DIPROPIONATE Respiratory CEP BETAMETHASONE ACETATE Inflammation BETAMETHASONE BASE Dermatology CEP BETAMETHASONE DIPROPIONATE Dermatology CEP BETAMETHASONE VALERATE Dermatology CEP BICALUTAMIDE Oncology CEP BIMATOPROST Ophthalmology 2 Product Known Teva Tech US EU Japan Korea therapeutic api file*** DMF DMF DMF DMF area** IP B BIVALIRUDIN Hematology BLEOMYCIN SULFATE Oncology BORTEZOMIB Oncology BREXANOLONE Neurology-Psychiatry BREXPIPRAZOLE Neurology-Psychiatry BROMOCRIPTINE MESYLATE Cardiovascular CEP BUDESONIDE Respiratory CEP BUPRENORPHINE BASE Neurology-Psychiatry CEP BUPRENORPHINE HCl Neurology-Psychiatry CEP BUTORPHANOL TARTRATE Analgesic C CABAZITAXEL Oncology CABERGOLINE Prolactinoma treatment CEP CALCIPOTRIENE* Immunology CEP CALCITRIOL Endocrinology & metabolism CEP CANDESARTAN CILEXETIL Cardiovascular CEP CARBIDOPA Parkinson CEP CARBOPLATIN Oncology CEP CARFILZOMIB Oncology CARVEDILOL PHOSPHATE Cardiovascular CASPOFUNGIN ACETATE Infectious disease CHLORMADINONE ACETATE Endocrinology & metabolism CICLOSPORINE Immunology CEP CILOSTAZOL Coagulation Inhibitors CINACALCET HCl Endocrinology & metabolism CISATRACURIUM BESYLATE Muscle relaxant CEP CISPLATIN Oncology CEP CLARITHROMYCIN Infectious disease CEP CLOBETASOL PROPIONATE Dermatology CEP * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 3 Product Known Teva Tech US EU Japan Korea therapeutic api file*** DMF DMF DMF DMF area** IP C CLOPIDOGREL BISULFATE* Coagulation Inhibitors CEP CRISABOROLE Dermatology CYPROTERONE ACETATE Endocrinology & metabolism CEP D DABIGATRAN ETEXILATE Coagulation Inhibitors DALBAVANCIN Infectious disease DALBAVANCIN Antibiotic DARIFENACIN HBr Incontinence DASATINIB* Oncology DAUNORUBICIN HCl Oncology CEP DEFERASIROX Hematology DEFEROXAMINE MESYLATE Hematology CEP DEPRODONE PROPIONATE Dermatology DESLORATADINE Allergology DESMOPRESSIN ACETATE Nocturia CEP DESONIDE Dermatology DESOXIMETASONE Dermatology DESOXYCORTICOSTERONE Immunology DESVENLAFAXINE BASE Neurology-Psychiatry DESVENLAFAXINE SUCCINATE Neurology-Psychiatry DEXAMETHASONE -17 VALERATE Inflammation DEXRAZOXANE (ICRF) Cardiovascular DIAZOXIDE Cardiovascular DIFLORASONE DIACETATE Dermatology DIFLUPREDNATE Ophthalmology DIHYDROERGOTAMINE MESYLATE Migraine CEP DIHYDROERGOTOXINE MESYLATE Neurology-Psychiatry CEP DILTIAZEM HCl Cardiovascular CEP DIMETHYL FUMARATE Immunology DIROXIMEL FUMARATE Immunology DOCETAXEL Oncology DOCOSANOL Antiviral DONEPEZIL HCl* Neurology-Psychiatry DORZOLAMIDE HCl Ophthalmology CEP 4 Product Known Teva Tech US EU Japan Korea therapeutic api file*** DMF DMF DMF DMF area** IP D DOXEPIN HCl Neurology-Psychiatry CEP DOXERCALCIFEROL Endocrinology & metabolism DOXORUBICIN HCl Oncology CEP DROSPIRENONE Endocrinology & metabolism CEP E EDOXABAN TOSYLATE Coagulation Inhibitors ELAGOLIX Genitourinary ELETRIPTAN HBr Migraine ELTROMBOPAG CHOLINE Hematology ELTROMBOPAG OLAMINE Hematology ELUXADOLINE Gastroenterology EMPAGLIFLOZIN Diabetes EPIRUBICIN HCl Oncology CEP EPTIFIBATIDE Hematology ERGOMETRINE (ERGONOVINE) MALEATE Postpartum haemorrhage CEP ERGOTAMINE TARTRATE Migraine CEP ERLOTINIB HCl* Oncology ESZOPICLONE Neurology-Psychiatry ETODOLAC Inflammation CEP ETOPOSIDE Oncology CEP EZETIMIBE Lipid lowering F FAMCICLOVIR Antiviral FEBUXOSTAT Rheumatology FINGOLIMOD HCl Immunology FLUDARABINE PHOSPHATE Oncology CEP FLUDROCORTISONE ACETATE Genitourinary FLUNISOLIDE* Respiratory FLUOCINOLONE ACETONIDE* Dermatology FLUOCINONIDE* Dermatology * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 5 Product Known Teva Tech US EU Japan Korea therapeutic api file*** DMF DMF DMF DMF area** IP F FLUOROMETHOLONE ACETATE Ophthalmology FLUOROMETHOLONE BASE Ophthalmology FLUOROURACIL - (5FU) Oncology CEP FLUOXETINE HCl Neurology-Psychiatry CEP FLUTICASONE FUROATE Respiratory FLUTICASONE PROPIONATE Respiratory CEP FLUVASTATIN SODIUM Lipid lowering CEP FORMOTEROL FUMARATE Respiratory CEP FULVESTRANT Oncology CEP FUROSEMIDE Cardiovascular CEP G GALANTAMINE HBr Neurology-Psychiatry CEP GEMCITABINE HCl Oncology CEP H HALOPERIDOL Neurology-Psychiatry HALOPERIDOL DECANOATE Neurology-Psychiatry HYDROCHLOROTHIAZIDE* Cardiovascular CEP Oncology I IBRUTINIB ICATIBANT ACETATE Angioedema IDARUBICIN HCl Oncology IMATINIB MESYLATE* Oncology CEP IMIPRAMINE HCl Neurology-Psychiatry CEP IMIQUIMOD Dermatology IRBESARTAN Cardiovascular CEP IVOSIDENIB Oncology IXAZOMIB CITRATE Oncology L LABETALOL HCl Cardiovascular CEP LAMOTRIGINE Epileptic CEP LANREOTIDE ACETATE Endocrinology & metabolism LANSOPRAZOLE Gastroenterology CEP LATANOPROST Ophthalmology LATANOPROSTENE BUNOD Ophthalmology LEDIPASVIR* Antiviral LETERMOVIR Antiviral 6 Product Known Teva Tech US EU Japan Korea therapeutic api file*** DMF DMF DMF DMF area** IP L LETROZOLE Oncology LEVOFLOXACIN Infectious disease LEVOSALBUTAMOL HCl (LEVALBUTEROL) Respiratory LIFITEGRAST Ophthalmology LINACLOTIDE Gastroenterology LINAGLIPTIN Diabetes LOPERAMIDE HCl Gastroenterology CEP LOSARTAN POTASSIUM AZIDE Cardiovascular CEP LOVASTATIN Lipid lowering CEP LURASIDONE HCl Neurology-Psychiatry M MACITENTAN Cardiovascular MAXACALCITOL Endocrinology & metabolism MEDROXYPROGESTERONE ACETATE Endocrinology & metabolism CEP MEGESTROL ACETATE Endocrinology & metabolism CEP MEMANTINE HCl Neurology-Psychiatry METHYLDOPA Cardiovascular CEP METHYLERGONOVINE MALEATE Postpartum haemorrhage CEP METHYLPREDNISOLONE HEMISUCCINATE Inflammation METOPROLOL SUCCINATE Cardiovascular CEP METOPROLOL TARTRATE Cardiovascular CEP MICAFUNGIN SODIUM Infectious disease MIDODRINE Cardiovascular MIDOSTAURIN* Oncology MIRTAZAPINE Neurology-Psychiatry CEP MITOMYCIN Oncology CEP MOMETASONE FUROATE* Respiratory CEP MONTELUKAST SODIUM* Respiratory CEP MUPIROCIN* Infectious disease CEP * Teva api can provide several different polymorphs or processes of this product To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager Additional DMF or Tech files are available upon request ** Therapeutic area = main indication *** Tech file relevant only for products prior to 1st DMF All subject to the disclaimer on last page 7 Product Known Teva Tech US EU Japan Korea therapeutic api file*** DMF DMF DMF DMF area** IP M MUPIROCIN CALCIUM Infectious disease CEP MYCOPHENOLATE MOFETIL Immunology CEP MYCOPHENOLATE SODIUM Immunology N NABUMETONE Inflammation CEP NERATINIB MALEATE Oncology NETARSUDIL MESYLATE Ophthalmology NICERGOLINE Cardiovascular CEP NIFEDIPINE Cardiovascular CEP NILOTINIB FUMARATE Oncology NILOTINIB HCl Oncology NILOTINIB TARTRATE Oncology NINTEDANIB ESYLATE Oncology NIRAPARIB TOSYLATE Oncology NITROFURANTOIN* Infectious disease NOMEGESTROL ACETATE Endocrinology & metabolism CEP NORGESTIMATE Endocrinology & metabolism O OBETICHOLIC ACID Immunology OCTREOTIDE ACETATE Endocrinology & metabolism OLANZAPINE Neurology-Psychiatry CEP OLMESARTAN MEDOXOMIL Cardiovascular CEP OLODATEROL HCl Respiratory OMEPRAZOLE Gastroenterology CEP ONDANSETRON BASE Gastroenterology ONDANSETRON HCl Gastroenterology CEP OSIMERTINIB MESYLATE Oncology OTRIVANCIN Infectious disease OXALIPLATIN Oncology CEP P PACLITAXEL Oncology CEP PALBOCICLIB Oncology PALIPERIDONE PALMITATE Neurology-Psychiatry PALONOSETRON HCl* Gastroenterology - Oncology PAMIDRONIC ACID Osteoporosis PANCURONIUM BROMIDE Muscle relaxant CEP 8 Product Known Teva Tech US EU Japan Korea therapeutic api file*** DMF DMF DMF DMF area** IP P PANTOPRAZOLE MAGNESIUM Gastroenterology PANTOPRAZOLE SODIUM Gastroenterology CEP PARICALCITOL Endocrinology & metabolism PAROXETINE HCl Neurology-Psychiatry PEMETREXED DIACID* Oncology PERAMPANEL Neurology-Psychiatry PERGOLIDE MESYLATE Parkinson CEP PIOGLITAZONE HCl Diabetes PLECANATIDE Gastroenterology PRALATREXATE Oncology PRASTERONE Endocrinology & metabolism PRASUGREL HBr Coagulation Inhibitors PRAVASTATIN SODIUM Lipid lowering CEP PREDNICARBATE Dermatology PREDNISOLONE HEMISUCCINATE Dermatology PREGABALIN Epileptic CEP PRILOCAINE Anesthetic PROBENECID Rheumatology CEP Q QUETIAPINE FUMARATE Neurology-Psychiatry CEP RAMELTEON Neurology-Psychiatry
Load more

Recommended publications
  • Eluxadoline: a Treatment for IBS with Diarrhoea in Adults
    ■ NEW PRODUCT Eluxadoline: a treatment for IBS with diarrhoea in adults STEVE CHAPLIN Eluxadoline (Truberzi) KEY POINTS is an oral mixed opioid- receptor agonist/ ■ Eluxadoline is an opioid-receptor agonist/antagonist with low systemic absorption antagonist licensed for ■ It is licensed for the treatment of irritable bowel syndrome with diarrhoea in the treatment of irritable adults and is recommended by NICE as a second-line agent bowel syndrome with ■ The recommended dosage is 75–100mg orally twice daily diarrhoea in adults. ■ In clinical trials, response rates were 27%–31% with eluxadoline and 19.5% with placebo after 26 weeks’ treatment This article examines its ■ Common adverse effects include constipation, nausea and abdominal pain properties, efficacy in ■ Pancreatitis and sphincter of Oddi spasm were uncommon adverse events clinical trials and side- ■ Treatment with eluxadoline costs £88.20 per month. effects. he initial management of irritable locally within the gastrointestinal tract, Tbowel syndrome (IBS) entails dietary slowing gastrointestinal transit, reducing and lifestyle change and treatment with urgency and improving stool consistency; antispasmodic agents.1 For people with its abuse potential is low. IBS and diarrhoea, loperamide is the anti- Eluxadoline is licensed for the treat- motility agent of first choice, adjusting the ment of IBS with diarrhoea in adults. The dose to achieve optimum stool consist- recommended dosage is 100mg twice ency. If this is unsatisfactory, treatment daily (reduced to 75mg twice daily if with a low-dose tricyclic antidepressant poorly tolerated). Treatment should be should be considered, with an SSRI a initiated at the lower dose in older people further option if this is unsuccessful.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Betamethasone
    Betamethasone Background Betamethasone is a potent, long-acting, synthetic glucocorticoid widely used in equine veterinary medicine as a steroidal anti-inflammatory.1 It is often administered intra-articularly for control of pain associated with inflammation and osteoarthritis.2 Betamethasone is a prescription medication and can only be dispensed from or upon the request of a http://en.wikipedia.org/wiki/Betamethasone#/media/File:Betamethasone veterinarian. It is commercially available .png in a variety of formulations including BetaVet™, BetaVet Soluspan Suspension® and Betasone Aqueous Suspension™.3 Betamethasone can be used intra-articularly, intramuscularly, by inhalation, and topically.4 When administered intra-articularly, it is often combined with other substances such as hyaluronan.5 Intra-articular and intramuscular dosages range widely based upon articular space, medication combination protocol, and practitioner preference. Betamethasone is a glucocorticoid receptor agonist which binds to various glucocorticoid receptors setting off a sequence of events affecting gene transcription and the synthesis of proteins. These mechanisms of action include: • Potential alteration of the G protein-coupled receptors to interfere with intracellular signal transduction pathways • Enhanced transcription in many genes, especially those involving suppression of inflammation. • Inhibition of gene transcription – including those that encode pro-inflammatory substances. The last two of these are considered genomic effects. This type of corticosteroid effect usually occurs within hours to days after administration. The genomic effects persist after the concentrations of the synthetic corticosteroid in plasma are no longer detectable, as evidenced by persistent suppression of the normal production of hydrocortisone following synthetic corticosteroid administration.6 When used judiciously, corticosteroids can be beneficial to the horse.
    [Show full text]
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • Fluorometholone Ophthalmic Suspension 0.1% W/V Corticosteroid Anti-Inflammatory
    PRODUCT MONOGRAPH PrFML® Fluorometholone Ophthalmic Suspension 0.1% w/v Corticosteroid Anti-Inflammatory Allergan Inc. Date of Preparation: Markham, ON October 30, 1972 L6G 0B5 Date of Revision: May 2, 2018 Submission Control No: 214474 Page 1 of 12 NAME OF DRUG Pr ® FML Fluorometholone Ophthalmic Suspension 0.1% w/v THERAPEUTIC CLASSIFICATION Topical corticosteroid ACTIONS Corticosteroids inhibit the inflammatory response to a variety of inciting agents of a mechanical, chemical and immunological nature. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, phagocytic activity, capillary proliferation, fibroblast proliferation, deposition of collagen and scar formation associated with inflammation. Corticosteroids are thought to act by controlling the rate of synthesis of proteins. Corticosteroids and their derivatives are capable of producing a rise in intraocular pressure. INDICATIONS FML® (fluorometholone ophthalmic suspension 0.1% w/v) is indicated for the treatment of steroid- responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. CONTRAINDICATIONS FML® is contraindicated in: Superficial (or epithelial) herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and other viral diseases of the cornea and conjunctiva. Fungal diseases of ocular structures. Mycobacterial infections of the eye (e.g., Tuberculosis of the eye). Acute untreated infections of the eye. Hypersensitivity to the constituents of this medication (for a listing of ingredients, see PHARMACEUTICAL INFORMATION), or hypersensitivity to other corticosteroids. Page 2 of 12 WARNINGS Use of topical corticosteroids may cause increased intraocular pressure (IOP) in certain individuals. It is necessary that the IOP be checked frequently in patients with a history of glaucoma. Use of corticosteroids may prolong the course and may exacerbate the severity of many viral eye infections (including herpes simplex).
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • Information for the User ZYTIGA 500 Mg Film-Coated Tablets Abiraterone
    Package leaflet: Information for the user ZYTIGA 500 mg film-coated tablets abiraterone acetate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What ZYTIGA is and what it is used for 2. What you need to know before you take ZYTIGA 3. How to take ZYTIGA 4. Possible side effects 5. How to store ZYTIGA 6. Contents of the pack and other information 1. What ZYTIGA is and what it is used for ZYTIGA contains a medicine called abiraterone acetate. It is used to treat prostate cancer in adult men that has spread to other parts of the body. ZYTIGA stops your body from making testosterone; this can slow the growth of prostate cancer. When ZYTIGA is prescribed for the early stage of disease where it is still responding to hormone therapy, it is used with a treatment that lowers testosterone (androgen deprivation therapy ). When you take this medicine your doctor will also prescribe another medicine called prednisone or prednisolone. This is to lower your chances of getting high blood pressure, having too much water in your body (fluid retention), or having reduced levels of a chemical known as potassium in your blood.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Abiraterone Acetate for Chemotherapy-Naive
    Fan et al. BMC Urology (2018) 18:110 https://doi.org/10.1186/s12894-018-0416-6 RESEARCHARTICLE Open Access Abiraterone acetate for chemotherapy- naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors Liancheng Fan†, Baijun Dong†, Chenfei Chi†, Yanqing Wang†, Yiming Gong†, Jianjun Sha, Jiahua Pan, Xun Shangguan, Yiran Huang, Lixin Zhou* and Wei Xue* Abstract Background: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. Methods: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate- specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. Results: The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23. 3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively.
    [Show full text]
  • A Note on Medical Management of Uveitis Apurupa Nedunuri Department of Pharmacology, Osmania University, Hyderabad, India
    OPEN ACCESS Freely available online e Journal of Pharmacovigilance ISSN: 2329-6887 Mini Review A Note on Medical Management of Uveitis Apurupa Nedunuri Department of Pharmacology, Osmania University, Hyderabad, India ABSTRACT Uveitis is a moving illness to treat. Corticosteroids have been utilized in the treatment of uveitis for a long time. Immunosuppressives are acquiring force lately in the treatment of uveitis. In this article we present an outline of current treatment of uveitis and the significant discoveries and advances in medications and visual medication conveyance frameworks in the treatment of uveitis. Keywords: Corticosteroids; Immunosuppressives; Medical Management; Uveitis. INTRODUCTION prednisolone acetic acid derivation is multiple times less powerful on a molar premise than betamethasone or dexamethasone, the Uveitis is a potentially sight threatening disease. It may occur due entrance into the cornea of prednisolone acetic acid derivation is to an infection or may be due to an autoimmune etiology. Specific significantly more than betamethasone or dexamethasone. Dosing antimicrobial therapies with or without corticosteroids are used recurrence and the time span the medicine stays in contact with in cases of infectious uveitis. Several drugs are available for the visual surface additionally impacts adequacy. Suspensions have a management of non-infectious uveitis including corticosteroids, immunosuppressive agents, and more recently biologics. The more serious level of calming impact. treatment of uveitis is evolving
    [Show full text]
  • 30 Day Change Notice Effective Date
    30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy
    [Show full text]